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1. Summary
Missense mutations in PTEN-induced kinase 1 (PINK1) cause autosomal-
recessive inherited Parkinson’s disease (PD). We have exploited our recent
discovery that recombinant insect PINK1 is catalytically active to test
whether PINK1 directly phosphorylates 15 proteins encoded by PD-associ-
ated genes as well as proteins reported to bind PINK1. We have
discovered that insect PINK1 efficiently phosphorylates only one of these
proteins, namely the E3 ligase Parkin. We have mapped the phosphorylation
site to a highly conserved residue within the Ubl domain of Parkin at Ser
65.
We show that human PINK1 is specifically activated by mitochondrial mem-
brane potential (Dcm) depolarization, enabling it to phosphorylate Parkin at
Ser
65. We further show that phosphorylation of Parkin at Ser
65 leads to
marked activation of its E3 ligase activity that is prevented by mutation of
Ser
65 or inactivation of PINK1. We provide evidence that once activated,
PINK1 autophosphorylates at several residues, including Thr
257, which is
accompanied by an electrophoretic mobility band-shift. These results provide
the first evidence that PINK1 is activated following Dcm depolarization and
suggest that PINK1 directly phosphorylates and activates Parkin. Our find-
ings indicate that monitoring phosphorylation of Parkin at Ser
65 and/or
PINK1 at Thr
257 represent the first biomarkers for examining activity of
the PINK1-Parkin signalling pathway in vivo. Our findings also suggest
& 2012 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
author and source are credited.that small molecule activators of Parkin that mimic the
effect of PINK1 phosphorylation may confer therapeutic
benefit for PD.
2. Introduction
The human PINK1 gene encodes a 581 residue serine–
threonine kinase unique among all protein kinases since it
contains an N-terminal mitochondrial targeting motif (resi-
dues 1–34) [1,2]. The catalytic domain of PINK1 (residues
150–513) is not closely related to other protein kinases and
is also unusual in that it possesses three unique insertions
between the beta strands that make up the typical fold of
the N-lobe of protein kinases [3]. PINK1 contains a conserved
C-terminal non-catalytic region of unknown function (resi-
dues 514–581). Great excitement in understanding the
regulation and function of this enzyme resulted from the
2004 landmark discovery that loss-of-function autosomal-
recessive mutations in PINK1 caused early onset PD [2]. Sub-
sequent studies in flies revealed that Drosophila PINK1 null
mutants share many overlapping features with human PD,
including motor deficits, neuronal loss and mitochondrial
abnormalities [4,5]. Other work in Drosophila [6] suggests
that PINK1 plays a role in regulating mitochondrial dynamics,
for example over-expression of PINK1 enhances mitochondrial
fission whilst loss of PINK1 leads to excess fusion.
Recent work in mammalian cellsp r o v i d e sf u r t h e rl i n k s
between PINK1 and the mitochondria. Current data suggest
that following recruitment of PINK1 to the mitochondrial mem-
brane via its N-terminal targeting sequence, it is subsequently
proteolysed between residues Ala
103–Phe
104 by the mitochon-
drial rhomboid protease, PARL [7–10], resulting in a processed
formofPINK1whichisrapidlydegradedbythe20Sproteasome
[1,11]. In response to mitochondrial membrane potential (Dcm)
depolarization, for example induced by the uncoupling agent
carbonyl cyanide m-chlorophenyl hydrazone (CCCP), a
marked stabilization of full length PINK1 at the mitochondria
is observed [12–15]. How CCCP stabilizes full-length PINK1 is
not known, but one proposal is that Dcm depolarization leads
to relocalization of PINK1 from the inner to the outer mitochon-
drial membrane where it is no longer accessible by PARL [8].
Despite considerable research, we still have limited knowl-
edge of the mechanism by which PINK1 kinase activity is
regulated, what substrates it might phosphorylate physiologi-
cally and how this links to PD. In our hands and those of
many other groups recombinant PINK1 expressed in mamma-
lian cells is inactive, which has limited the ability to use
traditionalbiochemicalapproachestoidentifyPINK1substrates.
Here,we have exploitedour recent discovery that insect ortholo-
guesofPINK1,includingTriboliumcastaneumPINK1(TcPINK1),
are catalytically active when expressed in Escherichia coli [3] to
investigate whether TcPINK1 was capable of phosphorylating
11 proteins encoded by genes linked to Mendelian-inherited
PD as well as seven proteins reported to bind PINK1. This excit-
inglyrevealedthatPINK1hadamarkedabilitytophosphorylate
one of these proteins, namely the RING E3 ligase, Parkin.
Autosomal-recessive inherited mutations in Parkin are one
of the most frequent causes of familial PD, especially young-
onset forms [16]. Since previous genetic analysis in Drosophila
[4,5] and mammalian cells [17] had suggested significant links
between PINK1 and Parkin and human patients with
mutations in either of these enzymes display very similar
clinical symptoms [18], we decided to further investigate the
phosphorylation of Parkin by PINK1. Our findings suggest
that both insect as well as human PINK1 directly phosphory-
late a highly conserved serine residue (Ser
65) lying within the
N-terminal Ubiquitin-like (Ubl) domain. We also present evi-
dence that CCCP and other agonists that depolarize the
Dcm specifically activate human PINK1 enabling it to phos-
phorylate Parkin at Ser
65 in vivo. We further establish the
functional importance of Ser
65 phosphorylation by demon-
strating that phosphorylation of Ser
65 leads to activation of
Parkin E3 ligase activity. We also present data that indicate
that once PINK1 is activated following CCCP treatment, it
autophosphorylates at several residues, including Thr
257,a n d
this is associated with an electrophoretic mobility band-shift
on an 8 per cent sodium dodecyl sulphate (SDS)-polyacryl-
amide gel. Our results indicate that PINK1 is activated
following CCCP treatment and that Parkin is a PINK1 sub-
strate. Our findings suggest that monitoring phosphorylation
of Parkin at Ser
65 and/or PINK1 at Thr
257 would be useful
as a reporter for PINK1-Parkin pathway activity. Our findings
also suggest that small molecule activators of Parkin may
confer a novel therapeutic approach for PD.
3. Results
3.1. Insect PINK1 phosphorylates Parkin in vitro
As some of the known PD-linked proteins may function in a
signalling network [19], we tested whether catalytically active
recombinant insect TcPINK1 could directly phosphorylate 11
different PD-linked proteins and seven putative PINK1 inter-
acting proteins (figure 1a,b). Strikingly, this revealed that
wild-type but not kinase-inactive TcPINK1 phosphorylated
full-length Parkin, but not any of the other proteins tested,
including Omi [20], TRAP1 [21] or Miro2 [22,23] (figure 1a,b).
3.2. Insect PINK1 phosphorylates Parkin at Ser
65,a
highly conserved residue within the Ubl domain
TcPINK1 phosphorylated Parkin in a time-dependent manner
reaching a maximal stoichiometry of phosphorylation of
approximately 0.25 moles of
32P-phosphate per mole of protein
(figure 1c).
32P-labelled Parkin was digested with trypsin and
analysed by chromatography on a C18 column. Two major
32P-labelled phosphopeptides were observed (figure 1d).
A combination of solid-phase Edman sequencing and mass
spectrometry revealed that both of these encompassed variants
of a peptide phosphorylated at Ser
65 (see electronic supplemen-
tary material, figure S1A and B). Ser
65 is located within the
N-terminal Ubl domain of Parkin and is highly conserved
from mammals to invertebrates (figure 1e). Mutating Ser
65 to
Ala prevented phosphorylation of full-length Parkin or an N-
terminal Parkin fragment containing the isolated Ubl domain
(residues 1–108) by TcPINK1 thereby confirming that this resi-
due represents the major site of PINK1 phosphorylation
(figure 1f ). The isolated Ubl domain of Parkin (residues
1–108) was phosphorylated to a significantly higher stoichi-
ometry than full-length Parkin in a parallel experiment
(figure 1f ). We also attempted to assess phosphorylation of a
longer C-terminal-truncated fragment of Parkin (residues
1–383) but were unable to do this rigorously as this fragment
was unstable (data not shown).
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23.3. PINK1 phosphorylation of Parkin at Ser
65 mediates
activation of Parkin E3 ligase activity
A recent study provided strong evidence that the Ubl domain of
Parkin acts as an auto-inhibitory domain by binding to a region
within the C-terminustherebysuppressing catalytic activity [24].
Given that Ser
65 lies within the core of the Ubl domain, we
hypothesized that phosphorylation of Ser
65 might relieve the
autoinhibition thereby activating the E3 ligase activity of
Parkin. To investigate this, we set up an E3 ligase auto-ubiquity-
lation assay to assess Parkin catalytic activity using an approach
that has been described previously employing highly purified
full length recombinant Parkin expressed in E. coli with no epi-
tope tags that can interfere with the autoinhibitory effect of the
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Figure 1. (Caption overleaf.)
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3Ubldomain[24].PriortoundertakingtheE3ligaseactivityassay,
we phosphorylated Parkin with increasing levels of TcPINK1 in
t h ep r e s e n c eo f
32P-adenosine triphosphate (ATP) so that we
could verify PINK1 was phosphorylating Parkin (middle
panels in figure 2). To assess Parkin E3 ligase activity, aliquots
of these reactions were added to a reaction containing E1 ubiqui-
tin-activating ligase, UbcH7 conjugating E2 ligase, ubiquitin and
Mg-ATP. After 60 min the reactions were terminated with SDS
sample buffer in the presence of dithiothreitol (DTT) and reac-
tions analysed by immunoblot analysis with antibodies that
detect ubiquitin, Parkin and TcPINK1. In the absence of PINK1
phosphorylation we confirmed previous findings and found
that Parkin displayed no significant E3 ligase activityand no evi-
denceofformationofpolyubiquitinchainswereobserved(lane1
on figure 2a). Excitingly, when increasing levels of TcPINK1
were added to the reaction at concentrations in which phos-
phorylation of Parkin was detected (middle panel of figure 2a),
we observed the marked dose-dependent appearance of non-
DTT-reducible low molecular weight polyubiquitylated species
migrating between approximately 30 and 50 kDa (top panel of
figure 2a).Consistent with this being mediated by phosphoryl-
ation of Parkin at Ser
65 by PINK1, the appearance of
polyubiquitin chains was inhibited by introducing a point
mutation in PINK1 that ablates catalytic activity (figure 2b)
or by mutating Ser
65 in Parkin to a non-phosphorylatable
Ala residue (figure 2c).
3.4. Evidence that human PINK1 phosphorylates Parkin
at Ser
65 in vivo
To investigate whether human PINK1 has the potential to phos-
phorylate Parkin, we over-expressed full-length human Parkin
in human HEK293 Flp-In TRex cells stably expressing wild-
type human PINK1, or kinase-inactive human PINK1 (D384A)
(figure3a). Cells were treated with or without themitochondrial
uncoupling agent, CCCP, for 3 h—conditionsthat induce stabil-
ization and activation of PINK1 at the mitochondria (see §2 and
also figure 6). Parkin was immunoprecipitated and phosphoryl-
ation site analysis undertaken by mass spectrometry. This
strikingly revealed that Parkin was phosphorylated at Ser
65,
but only in cells expressing wild-type human PINK1 that had
been stimulated with CCCP (figure 3a). No detectable phos-
phorylation of Ser
65 was observed in the absence of CCCP
treatment or in cells expressing kinase-inactive PINK1 (figure
3a). This result suggests that CCCP treatment might activate
PINK1 enabling it to phosphorylate Parkin (this is explored
below). We also detected phosphorylation of a previously
reported phosphorylation site (Ser
131). In contrast to Ser
65,p h o s -
phorylation of Ser
131 was constitutive and not modulated by
CCCPor PINK1 (figure 3a).Wefailedtodetect phosphorylation
of Parkin at another previously reported site (Thr
175) [25].
We next raised a phospho-specific antibody that specifi-
cally recognized Parkin phosphorylated at Ser
65 and used
this to confirm that Parkin phosphorylation at Ser
65 is mark-
edly induced by CCCP (3 h treatment) in HEK293 cells
expressing human wild-type but not kinase-inactive PINK1
in vivo (figure 3b). Moreover, mutation of Ser
65 to Ala
abolished recognition of Parkin in CCCP-treated cells over-
expressing wild-type PINK1 confirming the specificity of
the antibody we have generated. Interestingly, using the
phosphospecific Ser
65 antibody that is much more sensitive
than the mass spectrometry approach employed in analysis
of data in figure 3a, we also observed phosphorylation of
Parkin Ser
65 in cells not over-expressing PINK1 treated with
CCCP suggesting endogenous PINK1 present in HEK293 is
also able to phosphorylate Parkin (figure 3b).
To test whether we could detect endogenous PINK1 we
subjected HEK293 cell lysates to immunoprecipitation
employing a PINK1 antibody that we raised against a recom-
binant fragment of human PINK1 (residues 175–250) and
immunoblotted the immunoprecipitates with a commercial
Figure 1. (Overleaf.) TcPINK1 phosphorylates human Parkin at Ser
65 in vitro.( a) The indicated PD-linked proteins (1 mM) were incubated with either full-length
MBP-fusion of wild-type TcPINK1 (1–570) or kinase-inactive (KI) TcPINK1 (D359A) (0.5 mg) and [g-
32P] ATP for 30 min. Assays were terminated by addition of SDS
loading buffer and separated by SDS-PAGE. Proteins were detected by Colloidal Coomassie blue staining (lower panel) and incorporation of [g-
32P] ATP was detected
by autoradiography (upper panel). Similar results were obtained in three independent experiments. Fine dividing lines indicate that reactions were resolved on
separate gels. The substrate bands on the Coomassie gel are denoted with a small red asterisk. All substrates were of human sequence and expressed in E. coli unless
otherwise indicated. Tags on the substrates used for this experiment were glutathione s-transferase (GST)-a-synuclein, Parkin (no tag as His-SUMO tag cleaved off),
His-UCHL1, GST-DJ1, GST-LRRK2 KI (1326-end D2017A), MBP-ATP13A2, GST-Omi, MBP-PLA2G6, GST-FBX07, GST-GAK-kinase-inactive (D191A), VPS35 (no tag as GST-
tag cleaved off). (b)A si n( a) except that proteins reported to interact with PINK1 were tested as PINK1 substrates. Human DJ1, Omi, TRAP1, PARL, NCS1 and Miro2
were expressed in E. coli with an N-terminal GST tag. Similar results were obtained in three independent experiments. (c) Timecourse of phosphorylation of Parkin by
wild-type TcPINK1. MBP-TcPINK1 (0.5 mg) was incubated in the presence of GST-Parkin (1 mg) and [g-
32P] ATP for the times indicated and assays terminated by
addition of SDS loading buffer. Samples were subjected to SDS-PAGE and proteins detected by Colloidal Coomassie blue staining (lower panel) and incorporation of
[g-
32P] ATP was detected by autoradiography (upper panel). Gel pieces were quantified by Cerenkov counting for calculation of the stoichiometry of Parkin
phosphorylation. Similar results were obtained in two independent experiments. (d) Mapping of phosphopeptides on Parkin after phosphorylation by TcPINK1 in
vitro. Full-length GST-Parkin (1 mg) was incubated with 2 mg of either wild-type TcPINK1 (1–570) or KI TcPINK1 (D359A) in the presence of Mg
2þ[g-
32P] ATP for
60 min. Assays were terminated by addition of LDS loading buffer and separated by SDS-PAGE. Proteins were detected by Colloidal Coomassie blue staining and
phosphorylated Parkin was digested with trypsin. The resultant peptides were separated by reverse phase HPLC on a Vydac C18 column (Vydac 218TP5215)
equilibrated in 0.1% (v/v) trifluoroacetic acid and the column developed with an acetonitrile gradient (diagonal line). The flow rate was 0.2 ml min
21 and fractions
(0.1 ml each) were collected and analysed for
32P radioactivity by Cerenkov counting. Two major
32P-labelled peaks (P1, P2) were identified following incubation
with wild-type TcPINK1 (left). No peaks were identified following incubation with kinase-inactive TcPINK1 (right). (e) Schematic of domain organization of Parkin
illustrating that Ser
65 lies within the Ubl domain (upper panel) and sequence alignment of residues around Ser
65 in human Parkin and a variety of lower organisms
showing high degree of conservation. Abbreviations: Ubl, ubiquitin-like; IBR, in-between-RING; RING, really interesting new gene. (f ) Mutation of Ser
65Ala (S65A)
abolishes Parkin phosphorylation by TcPINK1. Full-length wild-type TcPINK1 (1–570) and kinase inactive TcPINK1 (D359A) against wild-type or S65A mutants of
full-length Parkin, or the isolated Ubl-domain-containing N-terminal fragment (residues 1–108). The indicated substrates (2 mM) were incubated in the presence of
the indicated enzyme (1 mg) and [g-
32P] ATP for 30 min. Assays were terminated by addition of SDS loading buffer and separated by SDS-PAGE. Proteins were
detected by Colloidal Coomassie blue staining (lower panel) and incorporation of [g-
32P] ATP was detected by autoradiography (upper panel).
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4PINK1 antibody (raised against residues 175–250; Novus
Biologicals). This revealed the presence of a band that
migrated at the size predicted for endogenous PINK1 and
that was strikingly stabilized by CCCP in a time-dependent
manner (up to 9 h; upper band figure 4a). This protein was
not observed in control immunoprecipitates undertaken
with pre-immune Immunoglobulin G (IgG; lower band
figure 4a). Consistent with this band representing endogen-
ous PINK1 it was significantly reduced when cells were
transfected for 48 h with two independent PINK1 siRNA
oligos but not scrambled siRNA (figure 4b). Importantly,
siRNA-mediated knockdown using two different siRNA
probes targeting PINK1 severely abrogated phosphorylation
of Parkin Ser
65, suggesting that the endogenous PINK1
protein does indeed regulate Parkin phosphorylation at
Ser
65 (figure 4b).
3.5. Human PINK1 isolated from CCCP-treated cells is
capable of phosphorylating Parkin in vitro
Our results suggest that human PINK1 is activated by CCCP
treatment and thereby rendered capable of phosphorylating
Parkin at Ser
65. To test this, we first immunoprecipitated
wild-type or kinase-inactive PINK1 from the mitochondrial
fraction of cells treated with CCCP and tested to see whether
it could phosphorylate the Ubl domain of Parkin in vitro
(figure 5). This revealed that wild-type PINK1 isolated from
CCCP-treated cells but not from non-treated cells could
indeed phosphorylate the Ubl domain of Parkin (figure 5).
Importantly, kinase-inactive PINK1 isolated from CCCP-
stimulated cells failed to phosphorylate the Ubl domain of
Parkin. Mutation of Ser
65 to Ala also prevented wild-type
PINK1 isolated from CCCP-stimulated cells from phos-
phorylating the Ubl domain of Parkin (figure 5). These
observations indicate that CCCP treatment is indeed leading
to the activation of human PINK1 enabling it to directly
phosphorylate Parkin at Ser
65.
3.6. Further evidence that CCCP promotes activation of
human PINK1 enabling it to autophosphorylate
at Thr
257 and other residues
We next studied the cellular localization and electrophoretic
mobility of wild-type and kinase-inactive human PINK1 in
response to CCCP (see §5). Similar to previous observations
[12–15] in non-CCCP-treated cells, full-length as well as a
truncated form of wild-type and kinase-inactive PINK1 was
present in both the cytoplasmic and mitochondrial fractions
(figure 6a). N-terminal Edman sequencing of the truncated
form of PINK1 confirmed that it commenced at residue 104
(see electronic supplementary material, figure S2) consistent
with previous work indicating that human PINK1 is proteo-
lysed between residues Ala
103–Phe
104 by the mitochondrial
rhomboid protease, PARL [7–10]. A 3 h CCCP treatment
induced a marked increase in the levels of the full-length
form of PINK1 associated with the mitochondria, which was
accompanied by a large reduction in cytoplasmic levels of
PINK1 (figure 6a). We also observed that CCCP treatment
led to a significant increase in levels of full-length PINK1 in
whole-cell extracts (figure 6a) consistent with CCCP stabilizing
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Figure 2. PINK1 phosphorylation of Parkin at Ser
65 mediates activation of Parkin E3 ligase activity. Wild-type (a) but not kinase-inactive (b) PINK1 activates wild-
type Parkin, but does not affect the activity of Ser
65Ala (S65A) mutant Parkin (c). Two micrograms of wild-type or S65A Parkin were incubated with indicated
amounts of wild-type or kinase-inactive (D359A) MBP-TcPINK in a kinase reaction (50 mM Tris-HCl (pH 7.5), 0.1 mM ethylene glycol tetraacetic acid (EGTA), 10 mM
MgCl2, 1% 2-mercaptoethanol and 0.1 mM [g-
32P] ATP (approx. 500 cpm pmol
21) (in parallel to confirm the phosphorylation) for 60 min. The ubiquitylation
reaction was then initiated by addition of ubiquitylation assay components (50 mM Tris-HCl (pH 7.5), 0.05 mM EGTA, 10 mM MgCl2, 0.5% 2-mercaptoethanol,
0.12 mM human recombinant E1 purified from Sf21 insect cell line, 1 mM human recombinant UbcH7 purified from E. coli, 0.05 mM Flag-Ubiquitin (MW approx.
9.5 kDa) (Boston Biochem) and 2 mM ATP). Reactions were terminated after 60 min by addition of SDS-PAGE loading buffer and resolved by SDS-PAGE. Ubiquitin,
Parkin and PINK1 were detected using anti-FLAG, anti-Parkin and anti-MBP antibodies, respectively. Incorporation of [g-
32P] ATP was detected by autoradiography
(lower panel). Ubiquitin attached to the E1 (Ub-Ube1) and ubiquitin dimer (Ub2) formation occurred in the assay in all conditions (a–c). Ubiquitylation of PINK1
(Ub-PINK1) is indicated (a). Formation of polyubiquitin chains (poly-Ub) upon Parkin activation (a) is indicated. As mentioned in §4, further work is required to
establish the nature of these chains and whether they are linked to UbcH7. Representative of five independent experiments.
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5full-length PINK1. Levels of full-length kinase-inactive PINK1
were also stabilized following CCCP treatment (figure 6a).
We also noticed that concomitant to inducing activation of
PINK1 and thereby Parkin phosphorylation (figures 3–5),
CCCP treatment induced a significant decrease in the
electrophoretic mobility (‘band-shift’) of the wild-type but
not kinase-inactive PINK1 (figure 6a). Many protein kinases
become capable of autophosphorylation at many residues
when activated and this frequently results in a band-shift of
the wild type but not a catalytically inactive mutant that is
incapable of autophosphorylation. This therefore prompted
us to investigate whether CCCP stimulated phosphorylation
of any residues on PINK1. We undertook mass spectrometric
phosphopeptide analysis of wild-type and kinase-inactive
full-length PINK1 after immunoprecipitation from mitochon-
drial fractions of CCCP-treated cells. This revealed that
several residues of PINK1 were phosphorylated in CCCP-
treated cells at low stoichiometry making the identification
of phosphorylation sites challenging. Thus far we have only
been able to unambiguously identify one of these phos-
phorylation sites, that corresponds to Thr
257 (figure 6b and
electronic supplementary material, figure S3). Employing a
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Figure 3. Human Parkin Ser
65 is a substrate of human PINK1 upon CCCP stimulation. (a) Confirmation by mass spectrometry that Ser
65 of human Parkin is
phosphorylated by CCCP-induced activation of human wild-type PINK1-FLAG. Flp-In T-Rex HEK293 cells expressing FLAG-empty, wild-type PINK1-FLAG, and kinase-
inactive PINK1-FLAG (D384A) were co-transfected with HA-Parkin, induced with doxycycline and stimulated with 10 mM of CCCP for 3 h. Whole-cell extracts were
obtained following lysis with 1% Triton and approximately 30 mg of whole-cell extract were subjected to immunoprecipitation with anti-HA-agarose and run on
10% SDS-PAGE and stained with colloidal Coomassie blue. Coomassie-stained bands migrating with the expected molecular mass of HA-Parkin were excised from the
gel, digested with trypsin, and subjected to high performance liquid chromatography with tandem mass spectrometry (LC-MS-MS) on an LTQ-Orbitrap mass
spectrometer. Extracted ion chromatogram analysis of Ser
131 and Ser
65 phosphopeptide (3
þ R.NDWTVQNCDLDQQSIVHIVQRPWR.KþP). The total signal intensity of
the phosphopeptide is plotted on the y-axis and retention time is plotted on the x-axis. The m/z value corresponding to the Ser
131 phosphopeptide was detected in
all conditions whilst that of the Ser
65 phosphopeptide was only detected in samples from wild-type PINK1-FLAG-expressing cells following CCCP treatment. (b)
Characterization of Parkin phospho-Ser
65 antibody. Flp-In T-Rex HEK293 cells expressing FLAG-empty, wild-type PINK1-FLAG, and kinase-inactive PINK1-FLAG were
co-transfected with untagged wild-type (WT) or Ser
65Ala (S65A) mutant Parkin, induced with doxycycline and stimulated with 10 mM of CCCP for 3 h. 0.25 mg of
1% Triton whole-cell lysate were subjected to immunoprecipitation with anti-Parkin antibody (S966C) covalently coupled to protein G Sepharose and then
immunoblotted with anti-phospho-Ser
65 antibody in the presence of dephosphorylated peptide. Ten per cent of the immunoprecipitate (IP) was immunoblotted
with total anti-Parkin antibody. Twenty five micrograms of whole cell lysate was immunoblotted with total PINK1 antibody.
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Figure 4. Knock-down of endogenous PINK1 abrogates Parkin Ser
65 phosphorylation. (a) Timecourse of endogenous PINK1 stabilization by CCCP treatment. HEK293 cells
were stimulated at the indicated time points with 10 mM of CCCP. One milligram of whole-cell lysates were immunoprecipitated with anti-PINK1 antibody (S085D) or
pre-immune IgG covalently coupled to protein G Sepharose and resolved by 8% SDS-PAGE. Immunoblotting was performed with total PINK1 antibody (Novus).
Representative of three independent experiments. (b) Knock-down of endogenous PINK1 abrogates Parkin Ser
65 phosphorylation. HEK293 cells were co-transfected with
PINK1 siRNA (#1 or #2) or scrambled siRNA (scrambled) and untagged wild-type (WT) or Ser
65Ala (S65A) mutant Parkin as indicated using TransFectin reagent (Bio-Rad).
Forty-eight hours post-transfection, cells were treated with or without 10 mM CCCP for 3 h. 0.25 mg of 1% Triton whole-cell lysate were subjected to
immunoprecipitation with GST-Parkin antibody (S966C) covalently coupled to protein G Sepharose and then immunoblotted with anti-phospho-Ser
65 antibody in the
presence of dephosphorylated peptide. Five per cent of the IP was immunoblotted with total anti-Parkin antibody. 0.25 mg of whole-cell lysates were immunoprecipitated
with anti-PINK1 antibody (S085D) and immunoblotted with anti-PINK1 antibody (Novus). Representative of three independent experiments.
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Figure 5. Human PINK1 directly phosphorylates Parkin Ser
65 upon CCCP stimulation in vitro. Flp-In T-Rex HEK293 cells expressing wild-type PINK1-FLAG, and kinase-
inactive PINK1-FLAG were induced to express protein by addition of 0.1 mgm l
21 of doxycycline in the culture medium for 24 h. Cells were then treated with
10 mM of CCCP for 3 h and lysates subjected to sub-cellular fractionation. Five milligrams of mitochondrial lysate was subjected to immunoprecipitation with anti-
FLAG agarose and used in an in vitro radioactive kinase assay with [g-
32P]-Mg
2þATP and E. coli expressed recombinant GST-Parkin Ubl domain (residues 1–108)
(Ubl) and mutant GST-Parkin (residues 1–108) Ser
65Ala (Ubl S65A), purified from E. coli. One half of the assay reaction was run on a 10% SDS-PAGE and was
subjected to autoradiography. Colloidal Coomassie stained gel shows equal loading of recombinant substrate. The other half of the reaction was immunoblotted with
anti-phospho-Thr
257 PINK1 and total PINK1 antibodies following 8% SDS-PAGE.
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7phosphospecific Thr
257 antibody that we raised, we were able
to confirm that CCCP treatment markedly stimulated phos-
phorylation of wild-type but not kinase-inactive PINK1 at
Thr
257 (figure 6c), suggesting that this residue is an autopho-
sphorylation site. Mutation of Thr
257 to Ala abolished
detection of phosphorylated PINK1 confirming the specificity
of the Thr
257 antibody (figure 6c). We also confirmed that the
active PINK1 we isolated from CCCP-treated cells and used to
phosphorylate the Ubl domain of Parkin (figure 5) was indeed
phosphorylated at Thr
257 (panel 3 in figure 5). Parkin Ser
65
phosphorylation was still observed in CCCP-treated cells
expressing the PINK1 Thr
257Ala mutant (figure 6d)s u g g e s t i n g
that phosphorylation of this residue is not required for CCCP-
induced PINK1 activation in vivo.M o r e o v e r ,t h eT h r
257Ala
mutation did not prevent the CCCP-induced band-shift indi-
cating that phosphorylation of this residue is not critical for
this (figure 6c,d). Thr
257 is located within the second insert
region (residues 247–270) and, like many autophosphorylation
sites in other protein kinases, is not highly conserved between
species. Nevertheless monitoring phosphorylation of this
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Figure 6. Identification and characterization of a novel autophosphorylation site of PINK1 induced by the mitochondrial uncoupling agent CCCP. (a) CCCP induces a
band-shift in wild-type but not kinase-inactive PINK1. Flp-In T-Rex HEK293 cell lines stably expressing FLAG alone, wild-type or kinase-inactive PINK1-FLAG were
induced to express protein by addition of 0.1 mgm l
21 of doxycycline in the culture medium for 24 h. Cells were then treated with 10 mM of CCCP for 3 h and
lysates subjected to sub-cellular fractionation. Twenty-five micrograms of cytoplasmic or mitochondrial lysate were resolved by 8% SDS-PAGE. Relative purity of the
fractions was confirmed using cytoplasmic and mitochondrial markers, namely GAPDH and HSP60, respectively. Whole-cell extracts from the same cells were also
made in parallel using 1% Triton lysis as described in the methods. In mitochondrial and whole-cell extracts, both wild-type and kinase-inactive PINK1 became
stabilized by CCCP but a band-shift was noted for wild-type PINK1 which was revealed to be a doublet on lower exposure. The upper band was absent from kinase-
inactive PINK1 treated with CCCP. (b) Identification of Thr
257 phosphorylation site on PINK1. Flp-In T-Rex HEK293 cell lines stably expressing FLAG alone, or wild-type
PINK1-FLAG were treated with DMSO or 10 mM of CCCP for 3 h. Recombinant PINK1 was immunoprecipitated from 10 mg of mitochondrial extract for each
condition using anti-FLAG-agarose and subjected to 4–12% gradient SDS-PAGE and stained with colloidal Coomassie blue. The Coomassie-stained bands migrating
with the expected molecular mass of PINK1-FLAG were excised from the gel, digested with trypsin, and subjected to precursor-ion scanning mass spectroscopy. The
major phosphopeptide that is indicated ‘Thr
257’ was seen from cells expressing wild-type PINK1-FLAG treated with CCCP and this was not seen in bands from the
other two conditions. The figure shows the signal intensity (cps, counts of ions per second) of the HPO3
2 ion (279 Da) seen in negative precursor ion scanning
mode versus the ion distribution (m/z) for the Thr
257 phosphopeptide. The observed values of 722.4 and 788.4 are for the VALAGEYGAVTYR and VALAGEYGAVTYRK
variants, respectively, of the Thr
257 peptide as [M-2H]
22 ions. Other phosphopeptides marked with an asterisk were observed but we were unable to assign
phosphorylation site(s). (c) Evidence that CCCP induces PINK1 auto-phosphorylation using a phospho-specific Thr
257 antibody. 0.5 mg of mitochondrial extracts
(treated with DMSO or 10 mM of CCCP for 3 h) of Flp-In T-Rex stable cell lines expressing FLAG empty, wild-type PINK1-FLAG, kinase-inactive PINK1-FLAG (D384A)
and phospho-mutant Thr
257Ala (T257A) were immunoprecipitated with anti-FLAG agarose and resolved by 8% SDS-PAGE. Blots were probed with anti-phospho-
Thr
257 PINK1 antibody and anti-PINK1 antibody. (d) Mutation of Thr
257Ala PINK1 does not affect Parkin Ser
65 phosphorylation. Flp-In T-Rex HEK293 cells expressing
FLAG-empty, wild-type PINK1-FLAG, kinase-inactive PINK1-FLAG and T257A PINK1-FLAG were co-transfected with untagged wild-type (WT) or Ser
65Ala (S65A)
mutant Parkin, induced with doxycycline and stimulated with 10 mM of CCCP for 3 h. 0.25 mg of 1% Triton whole-cell lysate were subjected to
immunoprecipitation with anti-Parkin antibody (S966C) covalently coupled to protein G Sepharose and then immunoblotted with anti-phospho-Ser
65 Parkin antibody
in the presence of dephosphorylated peptide. Ten per cent of the IP was immune-blotted with total anti-Parkin antibody. One milligram of 1% Triton whole-cell
lysate were immunoprecipitated with anti-FLAG agarose and resolved by 8% SDS-PAGE. Blots were probed with anti-phospho-Thr
257 PINK1 and anti-PINK1 antibody.
(e) PINK1 dephosphorylation by lambda phosphatase inhibits PINK1 activity. C-terminal-FLAG tagged wild-type or kinase-inactive (D384A) PINK1 were
immunoprecipitated from 5 mg of mitochondrial enriched extracts using anti-FLAG agarose beads. Wild-type PINK1 was incubated with or without 1000 U of
lambda phosphatase or treated with lambda phosphatase along with 50 mM EDTA. Kinase-inactive PINK1 was incubated in buffer alone without lambda
phosphatase. The beads were washed thrice in 50 mM Tris pH 7.5, 0.1 mM EGTA and then used in an in vitro kinase assay with GST-Parkin Ubl (1–108) as the
substrate. Samples were analysed as described in legend to figure 1.
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8residue could serve as a useful marker for PINK1 activity at
least until better reporters for PINK1 activation are identified.
We next investigated how phosphatase treatment affects
CCCP-induced PINK1 activity. We found that lambda phos-
phatase treatment of PINK1 isolated from CCCP-treated cells
induced complete dephosphorylation of Thr
257,a n da l s o
resulted in a significant inhibition of PINK1 activity as
judged by its ability to phosphorylate Parkin. Addition of the
lambda phosphatase inhibitor EDTA prevented dephosphory-
lation of Thr
257 and loss of the ability of PINK1 to
phosphorylate Parkin. Given that Thr
257 phosphorylation is dis-
pensable for Parkin Ser
65 phosphorylation in vivo (figure 6d),
this suggests that phosphorylation of PINK1 at additional
sites other than Thr
257 may be important in mediating the acti-
vation of PINK1 induced by CCCP (figure 6e). We also
observed that phosphatase treatment did not collapse the
CCCP-induced band-shift (figure 6e), indicating that either
phosphatase-resistant sites or another type of protein
modification mediates the band-shift.
3.7. Timecourse of PINK1 activation,
autophosphorylation and phosphorylation of
Parkin
We next investigated the timecourse of the PINK1 stabilization,
band-shift, autophosphorylation of Thr
257 and ability of PINK1
to phosphorylate Parkin following CCCP treatment. This
revealed that the stabilization of full-length PINK1 at the mito-
chondria is rapid with significant stabilization seen within
5 min of CCCP treatment and is maximal by 40 min and
then sustained for up to 3 h (figure 7a). Loss of the cleaved
form of PINK1 observed in the cytosol is particularly rapid
and almost disappears within 5 min of CCCP treatment
(figure 7b). However, the appearance of the band-shift and
autophosphorylation of Thr
257 occurred more slowly and was
observed only after 40 min of CCCP treatment and was
sustained for up to 3 h (figure 7a). There was no phosphoryl-
ation of Thr
257 or band-shift of cytoplasmic-associated PINK1
indicating that mitochondrial association is required for this
(figure 7b). In contrast, monitoring Parkin Ser
65 phosphoryl-
ation using the phospho-specific antibody against phospho-
Ser
65 indicated that Parkin Ser
65 phosphorylation occurs at
5 min (figure 7c) and becomes maximal and sustained from
40 min onwards. This suggests that the kinetics of PINK1 acti-
vation against its substrate are significantly faster than the
kinetics of PINK1 autophosphorylation.
3.8. PINK1 is activated specifically by depolarization of
the inner mitochondrial membrane potential
Within the inner mitochondrial membrane (IMM), the elec-
tron transport chain transfers electrons through a series of
oxidation–reduction reactions coupled to the transfer of pro-
tons across the IMM and this efflux creates a proton
electrochemical gradient known as the protomotive force.
The protomotive force drives the re-entry of protons through
the proton channel of the F1F0-ATP synthase crucial for ATP
production and comprises mainly of an electrical com-
ponent—the mitochondrial membrane potential (Dcm)—
and a transmembrane pH gradient [26]. CCCP dissipates
both Dcm and the pH gradient leading to impaired
mitochondrial ATP synthesis. To determine the mechanism
of activation of PINK1, we tested a panel of agonists that
have previously been reported to disrupt mitochondria by
diverse modes of action (figure 8a). Under the conditions
tested only the proton ionophores CCCP, FCCP and the pot-
assium uniporter valinomycin were able to induce activation
of PINK1 leading to Parkin Ser
65 phosphorylation (figure 8b).
In contrast to CCCP and FCCP, valinomycin depolarizes the
Dcm but does not affect the pH gradient suggesting that
PINK1 is specifically activated by loss of the Dcm. We did
not observe any effect of an inhibitor of ATP synthase (oligo-
mycin) or various inhibitors of the electron transport chain
complexes that have previously been implicated in neurode-
generation models (MPPþ, rotenone, 3-nitropropionic acid).
4. Discussion
Our data indicate that PINK1 is activated following mito-
chondrial membrane potential (Dcm) depolarization and
that PINK1 directly phosphorylates Parkin at Serine 65
(Ser
65) inducing its activation. Previous observations indicat-
ing that Drosophila dPINK1 and dParkin null flies have
similar degenerative phenotypes [4,5] and that over-
expression of Parkin rescues the phenotype of dPINK1 null
Drosophila (but not the converse) are consistent with PINK1
acting upstream of Parkin [4,5]. The ability of PINK1 to regu-
late mitochondrial dynamics in mammalian cells as well as
Drosophila has also been suggested to be dependent upon
Parkin [6,17,27–29]. The finding that humans with loss-
of-function mutations in either PINK1 or Parkin display
indistinguishable clinical presentation of PD also argues in
favour of a major connection between PINK1 and Parkin
in humans [18].
Parkin belongs to the RING-in-between-RING (RBR)
family of ubiquitin ligases and recent work suggests that
Parkin as well as other RBR family members may function
as RING/HECT hybrids that use the HECT-preferred E2,
UbcH7, and catalyse transfer of ubiquitin to substrates via
an intermediate thioester-linked ubiquitin adduct on a con-
served cysteine in the RING2 domain (Cys
431) [30]. It was
recently proposed that the Ubl domain of Parkin acts as an
auto-inhibitory domain by binding to the C-terminal region
and preventing catalytic activity by sterically preventing ubi-
quitin binding to the C-terminus [24]. However, the
mechanism of activation of Parkin remained unknown [24].
Inspection of all the available structures, both nuclear
magnetic resonance (NMR) and crystal, reveals that Ser
65
may sometimes lie within the fifth b-strand that makes up
the ubiquitin-like fold and is partially exposed to the surface
(PDB code 2KNB (solution, mouse) [31]; PDB code 1IYF (sol-
ution, human) [32]; see electronic supplementary material,
figure S4) or sometimes may lie within a loop adjacent to
the strand (PDB code 1MG8 (solution, mouse) [33]; PDB
code 2ZEQ (crystal, mouse) [34]) suggesting some confor-
mational flexibility around this element. It is therefore
possible that upon interaction with PINK1, the Ubl domain
undergoes a local conformational change enabling PINK1
to gain access to Ser
65 for phosphorylation. One possibility
is that phosphorylation at Ser
65 may perturb the b-strand
formation in the Ubl domain leading to loss of the autoinhi-
bition and subsequent activation of Parkin. Indeed previous
work has shown that this region of the Ubl domain in
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9which Ser
65 lies is critical for maintaining the autoinhibition
[24]. In future work it would be critical to study the biophysi-
cal interaction between PINK1 and Parkin, define the
interacting domains in more detail and establish how phos-
phorylation of Ser
65 impacts on this interaction leading to
the activation of Parkin. The finding that phosphorylation
of full-length Parkin is much less efficient than phosphoryl-
ation of the isolated Ubl-domain suggests that other factors
might regulate the ability of PINK1 to phosphorylate
Parkin at Ser
65, which would be interesting to investigate in
future studies.
In this study, we have assessed Parkin E3 ligase activity
employing an auto-ubiquitylation assay that establishes that
following Ser
65 phosphorylation, Parkin in the presence of an
E1, and the E2, UbcH7, is capable of inducing the formation
of short polyubiquitylated chains. In future work, it would
be vital to repeat these assays employing physiological
Parkin substrate(s) to confirm that Ser
65 phosphorylation of
Parkin does indeed enhance the ubiquitylation of a genuine
Parkin substrate. In our assay, it is possible that these short
polyubiquitylated chains are covalently attached to the E2,
UbcH7, since in a recent study of the RBR family member,
HHARI, similar ubiquitin species were produced by HHARI
catalytic activity, which were attributed to HHARI E3-depen-
dent ubiquitylation of UbcH7 [30]. Further work will be
required to determine the nature of these ubiquitin species
and whether or not they are linked to UbcH7. It will also be
exciting to test the effect of disease mutants located within
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Figure 7. Timecourse of CCCP-induced activation of PINK1. (a) Timecourse of PINK1 autophosphorylation in vivo. Flp-In T-Rex HEK293 cells stably expressing
PINK1-FLAG wild-type and kinase-inactive (D384A) were stimulated at the indicated time points with 10 mM of CCCP. 0.5 mg of mitochondrial extracts were
immunoprecipitated with anti-FLAG agarose and resolved by 8% SDS-PAGE. Immunoblotting was performed with anti-phospho-Thr
275 antibody or total PINK1
antibody. (b) No time-dependent activation of cytoplasmic PINK1 in vivo.A si n( a) cytoplasmic extracts were obtained at the indicated time-points and
immunoprecipitated with anti-FLAG agarose and resolved by 8% SDS-PAGE. Immunoblotting was performed with PINK1 anti-phospho-Thr
275 antibody or total PINK1
antibody. (c) Timecourse of Parkin Ser
65 phosphorylation in vivo. Flp-In T-Rex HEK293 cells stably expressing wild-type PINK1-FLAG were co-transfected with
untagged wild-type (WT) or Ser
65Ala (S65A) mutant Parkin; induced with doxycycline and stimulated with 10 mM of CCCP at the indicated time points. 0.25 mg of
1% Triton whole-cell lysate were subjected to immunoprecipitation with anti-Parkin antibody (S966C) covalently coupled to protein G Sepharose and then
immunoblotted with anti-phospho-Ser
65 antibody in the presence of dephosphorylated peptide. One per cent of the IP was immunoblotted with total anti-Parkin
antibody. 1.5 mg of whole-cell extracts were immunoprecipitated with anti-FLAG agarose and resolved by 8% SDS-PAGE. Immunoblotting was performed with total
PINK1 antibody.
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10and out with the Ubl domain as well as a mutant of cysteine
(Cys
431) on the catalytic activity of Parkin.
Our data provide fundamental insights into the regu-
lation of Parkin and elaborate a signalling pathway that
may be central to neuronal loss in PD (figure 9). Our data
would suggest that loss-of-function mutations in PINK1
would lead to suppression of Parkin E3 ligase activity and
result in reduced ubiquitylation of Parkin’s targets. This
may explain why over-expression of Parkin in dPINK1 null
Drosophila restores ubiquitylation of targets and rescues the
null phenotype [4,5]. It is possible that the key Parkin targets
are located at the mitochondria and indeed several candidate
mitochondrial substrates for Parkin have been proposed,
including Mitofusin1 [35], VDAC1 [12] and more recently
PARIS [36] and Miro [37]. In future work, it would be vital
to test whether phosphorylation of Parkin at Ser
65 influences
its ability to ubiquitylate these or other targets and define
how this links to PD. Our data also suggest that small mol-
ecules that bind to and disrupt the Ubl domain-C-terminus
auto-inhibitory interface may activate Parkin in a similar
manner to Ser
65 phosphorylation. If Parkin inactivation
occurs in sporadic PD patients in addition to those
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Figure 8. PINK1 is specifically activated by inducers of mitochondrial membrane depolarization. (a) Table of agonists tested. (b) PINK1 phosphorylation of Parkin at
Ser
65 is specific to mitochondrial uncouplers. Flp-In T-Rex HEK293 cells expressing wild-type PINK1-FLAG were co-transfected with untagged wild-type Parkin,
induced with 0.1 mgm l
21 doxycycline for 24 h and stimulated with the indicated agonists for 3 h except for Deferiprone (24 h treatment). 0.25 mg of 1% Triton
whole-cell lysate was subjected to immunoprecipitation with anti-Parkin antibody (S966C) covalently coupled to protein G Sepharose and then immunoblotted with
anti-phospho-Ser
65 antibody in the presence of dephosphorylated peptide. Ten per cent of the IP was immunoblotted with total anti-Parkin antibody. Twenty-five
micrograms of whole-cell lysate was immunoblotted with total PINK1 antibody (Novus), phospho-JNK (CST), total-JNK (CST), phospho-ERK1/2, total-ERK1/2 (CST),
phospho-ACC (CST), total ACC (CST), phospho-AMPK (CST) and total AMPK (CST). Representative of two independent experiments.
UBL
RING0
RING2
RING1 IBR
UBL
RING0
RING2
RING1 IBR
‘closed’ inactive Parkin ‘open’ active Parkin
Ser65
PINK1
(CCCP) Dym
Figure 9. Model of Parkin activation by PINK1. Under basal conditions Parkin is kept in a closed inactive conformation by Ubl-mediated autoinhibition. Following
mitochondrial depolarization, PINK1 phosphorylates Parkin at Ser
65 thereby relieving Parkin autoinhibition and enabling Parkin to become active to ubiquitylate
target substrates.
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11harbouring PINK1 mutations, then such small molecule acti-
vators could hold significant therapeutic promise in
combating disease progression in PD.
In previous work, employing a positional scanning pep-
tide library approach, we elaborated an artificial peptide
substrate termed PINKtide that had the sequence
WIpYRRSPRRR. This was phosphorylated by an insect
orthologue, TcPINK1, albeit weakly with a Vmax of 8 U
mg
21 and a Km of 493 mM [3]. This contrasts with optimal
peptides for other active protein kinases that can usually be
phosphorylated with a Vmax of 100–1000 U mg
21 and Km
of less than 10 mM. Mutation of the þ1 Pro in PINKtide to
other residues tested inhibited phosphorylation, suggesting
that this residue might represent a key determinant for
PINK1 phosphorylation [3]. However, the sequence encom-
passing Ser
65 of Parkin, DLDQQSIVHI, is quite dissimilar
from PINKtide and does not possess a þ1 Pro residue. Our
Parkin data suggest that a þ1 Pro residue is not an essential
determinant for PINK1 phosphorylation. Previous studies,
based on co-immunoprecipitation and co-localization exper-
iments [38,39], have reported that PINK1 and Parkin bind
to each other and therefore it is possible that additional dock-
ing interactions between PINK1 and Parkin enable Ser
65 to be
efficiently phosphorylated. This may also explain why a short
peptide, encompassing Ser
65, synthesized by our laboratory
was not significantly phosphorylated by TcPINK1 (data
not shown).
There has been one previous report that human PINK1 iso-
lated from non-CCCP unstimulated cells can directly
phosphorylate Parkin at a single threonine residue, Thr
175,
[25]. In that study a deletion fragment of PINK1 spanning resi-
dues 200–581 was used that would be predicted to be missing
approximately the first 50 amino acids of the N-lobe of the
PINK1 kinase domain including the conserved glycine-rich
loop motif (residues 163–169), which in other kinases is essen-
tial for coordinating ATP. This construct of PINK1 would
therefore not be expected to be active in our opinion. More-
over, in that report, the kinase-inactive mutant of the PINK1
[200–581] fragment still exhibited substantial kinase activity
towards Parkin [25]. Taken together these findings indicate
that the phosphorylation of Thr
175 observed in this study
was likely to be mediated by a contaminating kinase. Our
experiments have also identified Ser
131 as a phosphorylation
site in Parkin that is constitutively phosphorylated and not
influenced by PINK1 or CCCP (figure 3a). Ser
131 lies within
the linker region of Parkin between the Ubl and RING0
domain and unlike Ser
65 is not fully conserved in lower organ-
isms (e.g. leucine in Drosophila). A previous in vitro study has
suggested that Ser
131 may be phosphorylated by Cdk5 [40],
and further work would be required to define the importance
of this phosphorylation site.
Our findings suggest that the full-length form of PINK1
becomes rapidly stabilized within 5 min of CCCP treatment
and this also coincides with the disappearance of the cleaved
form of PINK1 (figure 7a). PINK1 also becomes activated at
5 min and reaches maximal activity at 40 min as assessed
by monitoring phosphorylation of Parkin Ser
65 within cells
(figure 7c). However, the timecourse of PINK1 autopho-
sphorylation at Thr
257 takes longer, requiring around
40 min with activation then being sustained for at least up
to 3 h (figure 7a). It is not uncommon for kinases to exhibit
differential kinetics of catalytic activity for autophosphory-
lation as compared with substrate phosphorylation. The
kinetics for kinase activity against a substrate generally
occurs faster than autophosphorylation and is regarded as a
more reliable read-out of kinase activation. Interestingly, pre-
vious work has suggested that Parkin can translocate to the
mitochondria following CCCP treatment and that this is
enhanced when PINK1 is co-expressed in cells [12–15]. The
kinetics of Parkin translocation when PINK1 is co-expressed
is 5 min compared with 30 min when PINK1 is absent [14].
Given this is similar to the kinetics of Parkin phosphorylation,
it would be interesting to test whether phosphorylation of
Ser
65 influences the kinetics of Parkin translocation to
mitochondria in cells.
What drives the stabilization of full length PINK1 at the
mitochondria and destabilization of cleaved PINK1 is
unknown at present. One proposal is that the PARL pro-
tease-mediated cleavage is rapidly inhibited following
CCCP-induced depolarization in mitochondria thereby lead-
ing to stabilization of the full-length form of PINK1 [9],
while another report suggests that in the presence of CCCP,
PINK1 is relocated to the outer mitochondrial membrane ren-
dering it inaccessible by PARL [8]. The striking disappearance
of the cleaved form of PINK1 in the cytoplasm within 5 min
(figure 7b) also suggests that CCCP could trigger rapid degra-
dation of this form of PINK1 or else inhibit maturation and
processing of PINK1 in the cytosol by PARL-independent pro-
teolysis. In future work, it would be important not only to
investigate how full-length PINK1 is stabilized and the cleaved
form of PINK1 destabilized, but also to determine whether
simple recruitment of PINK1 to mitochondria is sufficient to
induce its activation or whether additional depolarization
and/or stabilization of the full-length form of PINK1 is a
pre-requisite for subsequent activation of PINK1.
It would also be essential to discover the mechanism by
which PINK1 is activated at the mitochondria following
CCCP treatment. Our data suggest that activation of PINK1
can be observed after immunoprecipitation and extensive
washing of the immunoprecipitate, which may be consistent
with a covalent modification. Lambda phosphatase treatment
substantially reduced PINK1 activation suggesting that phos-
phorylation is required for full activation (figure 6e). In future
work, it would be essential to establish what are the key
phosphorylation and/or other covalent modifications
induced by CCCP and whether these are responsible for trig-
gering activation of PINK1. Given the specificity of activation
of PINK1 by agonists that depolarize the Dcm (figure 8a,b), it
is also possible that PINK1 may become associated with a
non-covalent activator at the mitochondrial membrane, such
as another protein or a small molecule second messenger
that is recruited following Dcm depolarization. It would
also be interesting to investigate whether CCCP-mediated
generation of an intermediate molecular species, such as reac-
tive oxygen species, could modify PINK1 leading to its
activation.
Our data suggest that PINK1, like many kinases, autop-
hosphorylate at Thr
257 and probably other residues we have
not identified after it is activated. Based on multiple sequence
alignments, Thr
257 appears to lie within the centre of a region,
which is predicted to be an insertion loop and so would likely
be accessible for phosphorylation [3]. This is also associated
with an electrophoretic mobility shift on a polyacrylamide
gel after CCCP treatment of wild-type but not kinase-inactive
PINK1, which would be incapable of autophosphorylation
(figure 6a,b). It should be noted that this band-shift was
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12best observed by resolving proteins on an 8 per cent isocratic
polyacrylamide gel and was much less pronounced on gradi-
ent gels (see electronic supplementary material, figure S3).
This may explain why the band-shift of wild-type PINK1
following CCCP treatment has not been reported before.
Although our data suggest that autophosphorylation of
Thr
257 is not critical for triggering the activation of PINK1
we still feel that phospho-antibodies that recognize Thr
257
are likely to be a useful reporter of human PINK1 activation,
at least until a biomarker can be generated against the genu-
ine trigger of PINK1 activation, which is currently unknown.
Given the large body of evidence implicating mitochon-
drial dysfunction in PD [26], it would be important to
explore in subsequent work whether Ser
65 and perhaps
Thr
257 phosphorylation could have utility as specific bio-
markers for PD progression. It would also be interesting to
look at Ser
65 and Thr
257 phosphorylation in transgenic mouse
models of PD (e.g. a-synuclein) to determine whether this
pathway is implicated in other genetic forms of PD. It would
also be important to examine Ser
65 and Thr
257 phosphorylation
in brains and cell lines of patients with Parkin and PINK1
mutations and, more importantly, sporadic PD. In future
work, it would be important to raise state-of-the-art
biomarker-grade monoclonal antibodies against these residues.
In conclusion, we have added important new information
that supports the notion that PINK1 and Parkin function in a
common signalling pathway. Our data suggest that Dcm
depolarization induces stabilization and activation of
PINK1 at the mitochondria enabling it to directly phosphor-
ylate Parkin at Ser
65 within the N-terminal Ubl domain
leading to activation of the Parkin E3 ligase activity. We
also provide evidence that, once activated, PINK1 autopho-
sphorylates at several residues and this is associated with
an electrophoretic band-shift on a polyacrylamide gel. We
have identified one of these autophosphorylated residues as
Thr
257 and provided evidence that this could serve as a repor-
ter for PINK1 activation. Our findings provide reagents and a
framework for exciting follow-up studies. Firstly, it will be
crucial to understand how CCCP and other agents that
induce Dcm depolarization activate PINK1. It will also be
essential to identify the key substrates that Parkin ubiquity-
lates in response to Ser
65 phosphorylation. Hopefully such
information could provide valuable clues as to how disrup-
tion of the PINK1-Parkin signalling pathway leads to PD
and whether this pathway is also disrupted in patients with
the sporadic form of the disease. These studies are imperative
as they could lead to new ideas for therapies to treat PD in the
future, for example by developing a chemical probe that
activates Parkin by disrupting the Ubl-domain-mediated
autoinhibition of Parkin.
5. Material and methods
5.1. Reagents and general methods
Tissue culture reagents were from Life Technologies. [g-
32P]
ATP was from Perkin Elmer. The Flp-In T-Rex HEK293 cell
line was from Invitrogen and stable cell lines were generated
according to the manufacturer’s instructions by selection
with hygromycin. Restriction enzyme digests, DNA ligations
and other recombinant DNA procedures were performed
using standard protocols. All mutageneses were carried out
using the QuikChange site-directed mutagenesis method (Stra-
tagene) with KOD polymerase (Novagen). All DNA constructs
were verified by DNA sequencing, which was performed by
The Sequencing Service, School of Life Sciences, University
of Dundee, using DYEnamic ET terminator chemistry (Amer-
sham Biosciences) on Applied Biosystems automated DNA
sequencers. Parkin cDNA was cloned by PCR from a human
brain cDNA library and verified by sequencing (Ser223Pro
polymorphic variant; GenBank: BAA25751.1). DNA for mam-
malian cell transfection were amplified in E. coli DH5a strain
and plasmid preparation was done using Qiagen Maxi prep
Kit according to manufacturers protocol. DNA for bacterial
protein expression were transformed into E. coli BL21 DE3
RIL (codon plus) cells (Stratagene).
5.2. Cell culture and stimulations
Flp-In T-Rex stable cell lines were cultured using DMEM
(Dulbecco’s modified Eagle’s medium) supplemented with
10 per cent FBS (foetal bovine serum), 2 mM L-Glutamine,
1X Pen/Strep, 15 mgml
21 of Blasticidin and 100 mgm l
21 of
Hygromycin. Cell transfections of HA tagged Parkin or
untagged Parkin were performed using the polyethylenei-
mine method [41]. Cultures were induced to express
protein by addition of 0.1 mgml
21 of Doxycycline in the
medium for 24 h. To uncouple mitochondria, cells were trea-
ted with 10 mM CCCP (Sigma) dissolved in DMSO for the
indicated times. An equivalent volume of DMSO was used
as a control. In addition, cells were incubated with the follow-
ing agonists for 3 h including: 1 mM Oligomycin (Sigma),
10 mM Antimycin A (Sigma), 2 mM Valinomycin (Sigma),
10 mM FCCP (Sigma), 10 mM Dopamine (Sigma), 100 mM6 -
Hydroxy-dopamine (Sigma), 100 mM MPPþ (Sigma), 1 mM
rotenone (Sigma), 5 mM ionomycin (Sigma), 10 mM 3-nitro-
propionic acid (Sigma), 50 mM L-BSO (Sigma), 50 mM
hydrogen peroxide (Sigma), 100 mM Diamide (Sigma),
0.5 mM Doxorubicin (Sigma), 0.5 mM Phenformin (Sigma).
Cells were treated with 1 mM Deferiprone (3-Hydroxy-1,2-
dimethyl-4 (1H)-pyridone; Sigma) for 24 h.
5.3. siRNA knock-down of PINK1 expression
To knock down PINK1 gene expression, HEK293 cells were
transfected separately with two sets of Mission siRNA oligos
(Sigma) designated as siRNA #1 (50-CCAUCAAGAUGAU
GUGGAATT-30) or siRNA #2 (50-CAGAGAAGUGUUGU
GUGGATT-30) and scrambled control siRNA (Sigma). Cells
were transfected using TransFectin Lipid Reagent (Bio-Rad)
and incubated for 48 h before CCCP treatment. The final
concentration of siRNA was 30 nM. For detection of phos-
phorylated pSer
65-Parkin, 10 mg of untagged wild-type or
Ser
65Ala Parkin was co-transfected with siRNAs, respectively,
into the cells according to the above method.
5.4. Buffers and methods for mammalian cell lysis
Cells were lysed and fractionated by the indicated buffer and
methods: whole-cell lysis using buffer: 50 mM Tris/HCl (pH
7.4), 1 mM EGTA, 1 mM EDTA, 1% (w/v) 1 mM sodium
orthovanadate, 10 mM sodium b-glycerophosphate, 50 mM
NaF, 5 mM sodium pyrophosphate, 0.27 M sucrose, 1 mM
benzamidine and 2 mM phenylmethylsulfonyl fluoride
(PMSF) and 1% (v/v) Triton X-100. Lysates were clarified
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13by centrifugation at 13 000 r.p.m. for 10 min at 48C and the
supernatant was collected. Mitochondrial fractionation: cells
were lysed in buffer containing 250 mM sucrose, 20 mM
HEPES, 3 mM EDTA, 1% (w/v) 1 mM sodium orthovana-
date, 10 mM sodium b-glycerophosphate, 50 mM NaF,
5 mM sodium pyrophosphate, pH 7.5 and protease inhibitor
cocktail (Roche) at 48C. Cells were disrupted using a glass
hand-held homogenizer (20 passes) and the lysate was clari-
fied by centrifuging for 10 min at 800g at 48C. The
supernatant was further centrifuged at 16600g for 10 min.
The resultant supernatant served as the cytosolic fraction.
The pellet containing the mitochondrial fraction was resus-
pended in buffer containing 1 per cent Triton X-100 and
centrifuged at 13 000 r.p.m. for 10 min. This supernatant con-
tained solubilized mitochondrial proteins. All lysates were
snap-frozen at 2808C until use. Protein concentration was
determined using the Bradford method (Thermo Scientific)
with BSA as the standard.
5.5. Buffers for E. coli protein purification
Lysis buffer contained 50 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 5% (v/v) glycerol, 1%
(v/v) Triton X-100, 0.1% (v/v) 2-mercaptoethanol, 1 mM ben-
zamidine and 0.1 mM PMSF. Wash buffer contained 50 mM
Tris-HCl (pH 7.5), 500 mM NaCl, 0.1 mM EGTA, 5% (v/v) gly-
cerol, 0.03% (v/v) Brij-35, 0.1% (v/v) 2-mercaptoethanol, 1 mM
benzamidine and 0.1 mM PMSF. Equilibration buffercontained
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1 mM EGTA, 5%
(v/v) glycerol, 0.03% (v/v) Brij-35, 0.1% (v/v) 2-mercaptoetha-
nol, 1 mM benzamidine and 0.1 mM PMSF. Elution buffer was
equilibration buffer with the addition of 12 mM maltose. Sto-
rage buffer was equilibration buffer with the addition of
0.27 M sucrose and glycerol—PMSF and benzamidine were
omitted.
5.6. Protein purification from E. coli
Full length wild-type and kinase-inactive TcPINK1 was
expressed in E. coli as maltose binding protein (MBP) fusion
protein and purified as described previously [3]. Briefly,
BL21 Codonþ transformed cells were grown at 378Ct oa n
OD600 of 0.3, then shifted to 168C and induced with
250 mM IPTG (isopropyl b-D-thiogalactoside) at OD600 of
0.5. Cells were induced with 250 mM IPTG at OD 0.6 and
were further grown at 168C for 16 h. Cells were pelleted at
4000 r.p.m., and then lysed by sonication in lysis buffer.
Lysates were clarified by centrifugation at 30000g for
30 min at 48C followed by incubation with 1 ml per litre of
culture of amylose resin for 1.5 h at 48C. The resin was
washed thoroughly in wash buffer, then equilibration
buffer, and proteins were then eluted. Proteins were dialysed
overnight at 48C into storage buffer, snap-frozen and stored
at 2808C until use.
MBP-ATP13A2 and MBP-PLA2G6 were purified by similar
methods. GST-a-synuclein, GST-Parkin, GST-DJ1, GST-LRRK2
kinase inactive (KI) (1326-end D2017A), GST-Omi, GST-GAK
KI (D191A), GST-FBX07, untagged VPS35 (GST cleaved),
GST-TRAP1, GST-PARL, GST-NCS1 and GST-Miro2 were pur-
ified by similar methods except that recombinant GST-fusion
proteins were affinity purified on glutathione-Sepharose and
eluted with buffer containing 20 mM glutathione. GST-VPS35
was cleaved with GST-PreScission protease at 48C overnight.
His-UCHL1 was obtained from Ubiquigent (UK). His-SENP1
catalytic domain (residues 415–643) was purified as follows:
transformed BL21 cells were grown in LB (Luria Broth),
50 mgml
21 carbenicillin until OD600 ¼ 0.6, then induced with
300 mM IPTG (isopropyl b-D-1-thiogalactopyranoside) and
expressed overnight at 158C. The cells were collected, lysed
and the protein was purified using Ni
2þ-nitriloacetic acid-
Sepharose chromatography, followed by dialysis into 50 mM
HEPES pH 7.5, 10% glycerol, 150 mM NaCl, 1 mM DTT).
Untagged Parkin (His-SUMO cleaved) was expressed and
purified using a modified protocol from Helen Walden’s lab-
oratory [24]. BL21 cells were transformed with His-SUMO-
tagged Parkin constructs, overnight cultures were prepared
and used to inoculate 12   1 l LB medium, 50 mgml
21 carbeni-
cillin, 0.25 mM ZnCl2. The cells were grown at 378C until the
OD600 was 0.4 and the temperature was dropped to 168C. At
OD600 ¼ 0.8 expression was induced with 25 mM IPTG. After
overnight incubation the cells were collected and lysed in
75 mM Tris pH 7.5, 500 mM NaCl, 0.2 per cent Triton X-100,
25 mM imidazole, 0.5 mM tris(2-carboxyethyl)phosphine
(TCEP), 1 mM Pefablok, 10 mgml
21 Leupeptin. After soni-
cation and removal of insoluble material, His-SUMO-Parkin
was purified via Ni
2þ-NTA-Sepharose chromatography. The
protein was collected by elution with 400 mM imidazole in
50 mM Tris, pH 8.2, 200 mM NaCl, 10 per cent glycerol, 0.03
per cent Brij 35, 0.5 mM TCEP. This was dialysed twice against
50 mM Tris pH 8.2, 200 mM NaCl, 10 per cent glycerol,
0.5 mM TCEP in the presence of His-SENP1 415–643 at a
ratio of 1 mg His-SENP1 per 5 mg His-SUMO-Parkin. The pro-
tease, the His-SUMO tag and any uncleaved protein was
removed by two subsequent incubations with Ni
2þ–NTA–
Sepharose. The cleaved Parkin was further purified in
50 mM Tris, pH 8.2, 200 mM NaCl, 20 per cent glycerol, 0.03
per cent Brij, 0.5 mM TCEP over a Superdex 200 column.
5.7. Antibodies
The antibody against PINK1 phospho-Thr
257 (S114D) was
generated by injection of the KLH (keyhole-limpet haemo-
cyanin)-conjugated phospho-peptide CAGEYGAVpTYRK
SKR (where pT is phospho-threonine) into sheep and was
affinity-purified by positive and negative selection against
the phospho- and de-phospho-peptides, respectively. The
antibody against Parkin phospho-Ser
65 (S210D) was gener-
ated by injection of the KLH-conjugated phospho-peptide
RDLDQQpSIVHIVQR (where pS is phospho-serine) into
sheep and was affinity-purified by positive and negative
selection against the phospho- and de-phospho-peptides,
respectively. The antibody against total Parkin (S966C) was
raised in sheep against the recombinant GST-Parkin full-
length protein and successively affinity-purified by positive
and negative selection against recombinant fusion protein
and GST, respectively. The antibody against total PINK1
(S085D) was raised in sheep against a recombinant GST-
PINK1 fragment (residues 175–250) and successively puri-
fied by positive and negative selection against recombinant
fusion protein and GST, respectively. Anti-human PINK1
rabbit polyclonal (residues 175–250) antibody was obtained
from Novus Biologicals; anti-GAPDH mouse monoclonal
from Millipore; anti-Parkin mouse monoclonal (Santa
Cruz). Anti-HSP60 rabbit polyclonal, Anti-phospho-JNK,
Anti-total-JNK, Anti-phospho-ERK1/2, Anti-total-ERK1/2,
Anti-phospho-ACC, Anti-total ACC, Anti-phospho-AMPK
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14and Anti-total AMPK antibodies were all obtained from Cell
Signaling Technology. Anti-FLAG agarose beads were
obtained from Sigma.
5.8. Immunoprecipitation and immunoblotting
Immunoprecipitation of recombinant PINK1-FLAG was
undertaken by standard methods with anti-FLAG agarose
beads (Sigma); of HA-Parkin with anti-HA agarose beads
(Sigma); of untagged Parkin with anti-Parkin antibody
(S966C) covalently conjugated to protein G-Sepharose; and
of endogenous PINK1 with anti-PINK1 antibody (S085D) or
pre-immune IgG (negative control) covalently conjugated to
protein G-Sepharose. Immunoprecipitates, as well as cell
lysates in SDS sample buffer were subjected to SDS-PAGE
and transferred to PVDF membranes. For immunoblotting,
membranes were incubated for 60 min with 1 per cent Tris-
buffered saline with Tween (TBST) containing either 5%
(w/v) skimmed milk powder (for total antibodies) or 5%
(w/v) BSA (for phospho-specific antibodies). The antibodies
were then incubated in the same buffer overnight at 48C with
the indicated primary antibodies. Sheep total and phospho-
specific antibodies were used at a concentration of 1 mg
ml
21, whereas commercial antibodies were diluted 1000-
fold. The incubation with phospho-specific sheep antibodies
was performed with the addition of 10 mgml
21 of the depho-
sphopeptide antigen used to raise the antibody. Blots were
washed with 0.1 per cent TBST and incubated with secondary
HRP-conjugated antibodies in 5 per cent skimmed milk for
60 min. After repeated washes, the signal was detected with
enhanced chemiluminescence and the X-ray films were pro-
cessed in a Konica Minolta Medical SRX-101 film processor.
5.9. Kinase assays
In assays using E. coli-expressed wild-type or kinase-inactive
(D359A) MBP-TcPINK1, reactions were set up in a volume of
40 ml, with substrates at 1 mM and kinase at 0.5 mgi n5 0m M
Tris-HCl (pH 7.5), 0.1 mM EGTA, 10 mM MgCl2, 2 mM DTT
and 0.1 mM [g-
32P] ATP (approx. 500 cpmpmol
21). Assays
were incubated at 308C with shaking at 1200 r.p.m. and ter-
minated after the indicated time by addition of SDS sample
buffer. In mammalian HEK293 immunoprecipitation kinase
assays, C-terminal-FLAG tagged wild-type or KI (D384A)
PINK1 was immunoprecipitated from 5 mg of mitochondrial
enriched extracts using anti-FLAG agarose beads and activity
measured in a reaction volume of 40 ml consisting of 50 mM
Tris-HCl (pH 7.5), 0.1 mM EGTA, 10 mM MgCl2,2 m M
DTT, 0.1 mM [g-
32P] ATP (2000 cpmpmol
21) and 5 mMo f
indicated substrate. Assays were incubated at 308C with
shaking at 1200 r.p.m. and terminated after 30 min by
addition of SDS sample buffer. For all assays, reaction mix-
tures were resolved by SDS-PAGE. Proteins were detected
by Coomassie staining and gels were imaged using an
Epson scanner and dried completely using a gel dryer
(Bio-Rad). Incorporation of [g-32P] ATP into substrates was
analysed by autoradiography using Amersham Hyper-Film.
5.10. Lambda phosphatase assay
C-terminal-FLAG tagged wild-type or kinase-inactive (D384A)
PINK1 were immunoprecipitated from 5 mg of mitochondrial
enriched extracts using anti-FLAG agarose beads. Wild-type
PINK1 was incubated with or without 1000 U of lambda phos-
phatase (New England Biolabs) in a reaction volume of 40 ml
consisting of 50 mM Tris pH 7.5, 1 mM MnCl2 and 2 mM
DTT. In addition, wild-type PINK1 was treated with 1000 U
of lambda phosphatase in the presence of 50 mM EDTA.
Assays were incubated at 308C for 30 min with shaking at
1200 r.p.m. The beads were washed three times in 50 mM
Tris pH 7.5, 0.1 mM EGTA and then used in an in vitro
kinase assay with GST-Parkin Ubl (1–108) as the substrate.
Samples were further analyzed as described above.
5.11. In vitro assay of Parkin E3 ligase activity
Wild-type or Ser
65Ala Parkin (2 mg) were initially incubated
with the indicated amounts of E. coli-expressed wild-type
or kinase-inactive (D359A) MBP-TcPINK1 in a reaction
volume of 25 ml (50 mM Tris-HCl (pH 7.5), 0.1 mM EGTA,
10 mM MgCl2,1 %b-mercaptoethanol and 0.1 mM [g-
32P]
ATP (approx. 500 cpmpmol
21); in parallel to confirm the
phosphorylation). Kinase assays were incubated at 308C
with shaking at 1050 r.p.m. for 60 min followed by addition
of ubiquitylation assay components and Mastermix to a
final volume of 50 ml (50 mM Tris-HCl (pH 7.5), 0.05 mM
EGTA, 10 mM MgCl2, 0.5% 2-mercaptoethanol, 0.12 mM
human recombinant E1 purified from Sf21 insect cell line,
1 mM human recombinant UbcH7 purified from E. coli,
0.05 mM Flag-Ubiquitin (Boston Biochem) and 2 mM ATP).
Ubiquitylation reactions were incubated at 308C with shaking
at 1050 r.p.m. for 60 min and terminated by addition of SDS
sample buffer. For all assays, reaction mixtures were resolved
by SDS-PAGE. Ubiquitylation reactions were subjected to
immunoblotting with anti-FLAG antibody (Sigma, 1:7500),
anti-Parkin or anti-MBP antibodies. Incorporation of [g-32P]
ATP into substrates was analysed by autoradiography.
5.12. Mapping the site on human Parkin
phosphorylated by TcPINK1
GST-Parkin (1 mg) purified from E. coli was incubated with
2 mg of either wild-type MBP-TcPINK1 (1–570) or KI MBP-
TcPINK1 (D359A) for 60 min at 308C in 50 mM Tris-HCl
(pH 7.5), 0.1 mM EGTA, 10 mM MgCl2, 2 mM DTT and
0.1 mM [g-
32P] ATP (approx. 20000 cpmpmol
21) in a total
reaction volume of 25 ml. The reaction was terminated by
addition of lithium dodecyl sulphate (LDS) sample buffer
with 10 mM DTT, boiled and alkylated with 50 mM iodoace-
tamide before samples were subjected to electrophoresis on a
Bis–Tris 4–12% polyacrylamide gel, which was then stained
with Colloidal Coomassie blue (Invitrogen). Phosphorylated
Parkin was digested with trypsin and more than 95 per
cent of
32P radioactivity incorporated in the gel bands was
recovered. Peptides were chromatographed on a reverse
phase HPLC Vydac C18 column (Cat no. 218TP5215, Separ-
ations Group, Hesperia, CA) equilibrated in 0.1% (v/v)
trifluoroacetic acid and the column developed with a linear
acetonitrile gradient at a flow rate of 0.2 mlmin
21 and frac-
tions (0.1 ml each) were collected and analysed for
32P
radioactivity by Cerenkov counting. Isolated phosphopep-
tides were analysed by LC-MS-MS on a proxeon Easy-nLC
nano liquid chromatography system coupled to a Thermo
LTQ-orbitrap mass spectrometer. The resultant data files
were searched using Mascot (www.matrixscience.com) run
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15on an in-house system against a database containing the
Parkin sequence, with a 10 ppm mass accuracy for precursor
ions, a 0.8 Da tolerance for fragment ions, and allowing for
Phospho (ST), Phospho (Y), Oxidation (M) and Dioxidation
(M) as variable modifications. Individual MS/MS spectra
were inspected using XCALIBUR v. 2.2 software. The site of
phosphorylation of these
32P-labelled peptides was deter-
mined by solid-phase Edman degradation on an Applied
Biosystems 494C sequencer of the peptide coupled to Seque-
lon-AA membrane (Applied Biosystems) as described
previously [42].
5.13. Large-scale immunoprecipitation of mitochondrial
human PINK1 followed by identification of
phosphorylated Thr
257 by mass spectrometry
Ten milligrams of mitochondrial extract from Flp-In T-Rex
HEK293 cell lines stably PINK1–FLAG were subjected to
immunoprecipitation with anti-FLAG-agarose and then
eluted in LDS sample buffer. Samples were boiled with
10 mM DTT, and then alkylated with 50 mM iodoacetamide
before being subjected to electrophoresis on a Bis–Tris 4–
12% gradient polyacrylamide gel, which was then stained
with Colloidal Coomassie blue. Coomassie-stained bands
migrating with the expected molecular mass of PINK1–
FLAG were excised from the gel and digested with trypsin
and samples were analysed either by an Applied Biosystems
4000 Q-TRAP system with precursor ion scanning as
described previously [43] or on the LTQ-Orbitrap Velos
system with multistage activation.
5.14. Large-scale immunoprecipitation of human Parkin
followed by identification of phosphorylated Ser
65
by mass spectrometry
Flp-In T-Rex HEK293 cell lines stably expressing empty
vector, wild-type or kinase-inactive PINK1–FLAG were
sequentially co-transfected with HA-Parkin, induced with
0.1 mgml
21 of Doxycycline and then incubated with 10 mM
CCCP or DMSO control for 3 h before whole-cell lysis.
Approximately 30 mg of lysate was subjected to immunopre-
cipitation with anti-FLAG-agarose and then eluted in LDS
sample buffer. Samples were boiled with 10 mM DTT, and
then alkylated with 50 mM iodoacetamide before being sub-
jected to electrophoresis on a Bis–Tris 10 per cent
polyacrylamide gel, which was then stained with Colloidal
Coomassie blue. Coomassie-stained bands migrating with
the expected molecular mass of Parkin were excised from
the gel and digested with trypsin and samples underwent
phosphosite analysis with LTQ-Orbitrap Velos. Individual
MS/MS spectra of phosphopeptides were inspected using
XCALIBUR v. 2.2 software.
5.15. N-terminal Edman sequencing
HEK293 cells were transiently transfected with wild-
type PINK1-FLAG and then underwent whole-cell lysis.
One hundred milligrams of lysate was subjected to immuno-
precipitation with anti-FLAG agarose and then eluted in LDS
sample buffer. Samples were boiled with 10 mM DTT, and
then alkylated with 50 mM iodoacetamide before being
subjected to electrophoresis on a Bis–Tris 10 per cent poly-
acrylamide gel, which was then transferred to Immobilon
PVDF (polyvinylidene difluoride) membrane and stained
briefly with Coomassie Blue. The band corresponding to
the processed form of PINK1 was excised and subjected to
Edman degradation in an Applied Biosystems ProCise 494
Sequencer. The resulting HPLC profiles were analysed with
Model 610 software (Applied Biosystems).
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